---
schema_version: "secwatch.filing_event.v1"
accession: "0001731122-26-001000"
form_type: "8-K"
ticker: "AVXL"
cik: "0001314052"
company_name: "ANAVEX LIFE SCIENCES CORP."
filed_at: "2026-08-03T12:26:23+00:00"
generated_at: "2026-08-03T12:30:14.739108+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Anavex Life Sciences Announces Board Refresh, Nominates Two New Independent Directors

## Summary
- Nominates Gautam Patel and Dr. Adrian Senderowicz as new independent director candidates for 2026 Annual Meeting.
- Current board members Dr. Jiong Ma, Dr. Peter Donhauser, Dr. Axel Paeger, Dr. Claus van der Velden also stand for reelection.
- Urges stockholders to reject PVG Asset Management and Patrick Adams' attempt to replace entire board; PVG owns only 0.35% of shares.
- Former CEO Christopher Missling terminated for cause and not renominated; Dr. Terrie Kellmeyer appointed interim CEO.
- Company focuses on blarcamesine for Alzheimer's, Rett syndrome, Fragile X; strong cash runway, no long-term debt.

## SEC filing metadata
- accession: 0001731122-26-001000
- form_type: 8-K
- ticker: AVXL
- cik: 0001314052
- company_name: ANAVEX LIFE SCIENCES CORP.
- filed_at: 2026-08-03T12:26:23+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1314052/000173112226001000/0001731122-26-001000-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1314052/000173112226001000/e7823_8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001731122-26-001000
- JSON: https://secwatch.observer/filing/0001731122-26-001000.json
- Plain text: https://secwatch.observer/filing/0001731122-26-001000.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.